Q2 FY2026 · ended Jun 30, 2026 · Revenue $0, -100.0% YoY · Filed Aug 13, 2026
Guided Therapeutics, Inc. (GTHP) files with the SEC under industry code 3845, Electromedical & Electrotherapeutic Apparatus. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $605,000. As of Jun 30, 2026 it held $12,000 in cash and investments and $736,000 in total debt.
Revenue
$0
-100.0% vs year-ago quarter
Net income
$-605,000
+25.4% vs year-ago quarter
Operating cash flow
$-319,000
-88.8% vs year-ago quarter
Free cash flow
$-291,000
-4.3% vs prior quarter
EPS
$-0.01
+0.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
96.54M
+20.2% vs year-ago quarter
Net cash
$-724,000
Q2 FY2026
Operating margin
-303.8%
TTM
Company profile
- Industry
- Electromedical & Electrotherapeutic Apparatus (SIC 3845)
- Listed as
- GTHP (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Peachtree Corners, GA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 924515
- Former names
- SPECTRX INC (until Feb 28, 2008)
Other Electromedical & Electrotherapeutic Apparatus companies
- Medtronic plc MDT
- LivaNova PLC LIVN
- Integer Holdings Corp ITGR
- Axogen, Inc. AXGN
- TransMedics Group, Inc. TMDX
- CONMED Corp CNMD
- Ceribell, Inc. CBLL
- InMode Ltd. INMD
All 31 Electromedical & Electrotherapeutic Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $590,000 | $60,000 | $117,000 |
| Operating income | -$478,000 | -$302,000 | -$710,000 | -$485,000 | -$763,000 |
| Net income | -$605,000 | -$500,000 | -$1.2M | -$742,000 | -$811,000 |
| Diluted EPS | -$0.01 | -$0.01 | -$0.01 | -$0.01 | -$0.01 |
| Operating cash flow | -$319,000 | -$617,000 | -$291,000 | -$277,000 | -$169,000 |
| Free cash flow | — | — | -$291,000 | -$279,000 | — |
| Total assets | $1.2M | $1.6M | $1.3M | $903,000 | $940,000 |
| Total liabilities | $7.0M | $6.8M | $7.3M | $6.5M | $6.4M |
| Stockholders' equity | -$5.8M | -$5.2M | -$6.0M | -$5.6M | -$5.5M |
| Cash and investments | $12,000 | $369,000 | $63,000 | $87,000 | $185,000 |
| Total debt | $736,000 | $776,000 | $696,000 | $76,000 | $104,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Mar 31, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Mar 10, 2026 | Mar 2, 2026 |
| 10-Q | Quarterly report | Nov 13, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
All 1000 Guided Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.